SENORES PHARMACEUTICALS
|
SENORES PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 25.05 | 12.72 | 10.31 | 8.59 | 1.13 |
| CEPS(Rs) | 33.18 | 16.33 | 14.00 | 10.40 | 1.94 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 202.67 | 170.72 | 66.95 | 46.36 | 41.86 |
| Tax Rate(%) | 23.61 | 17.33 | -31.15 | 32.19 | 13.30 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 26.61 | 22.52 | 19.38 | 35.85 | 13.78 |
| EBIT Margin(%) | 29.11 | 23.13 | 16.03 | 41.25 | 12.05 |
| Pre Tax Margin(%) | 25.15 | 17.72 | 11.63 | 35.20 | 8.07 |
| PAT Margin (%) | 19.21 | 14.65 | 15.25 | 23.86 | 6.99 |
| Cash Profit Margin (%) | 24.15 | 18.88 | 19.91 | 28.90 | 11.97 |
| Performance Ratios | |||||
| ROA(%) | 8.64 | 6.43 | 8.86 | 8.89 | 1.69 |
| ROE(%) | 14.14 | 11.78 | 26.19 | 20.55 | 2.71 |
| ROCE(%) | 15.66 | 11.94 | 12.31 | 18.56 | 3.36 |
| Asset Turnover(x) | 0.45 | 0.44 | 0.58 | 0.37 | 0.24 |
| Sales/Fixed Asset(x) | 1.42 | 1.38 | 1.54 | 1.84 | 1.73 |
| Working Capital/Sales(x) | 1.63 | 0.83 | 62.91 | -64.72 | 0.83 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.70 | 0.73 | 0.65 | 0.54 | 0.58 |
| Receivable days | 129.44 | 108.09 | 114.09 | 215.56 | 505.67 |
| Inventory Days | 42.09 | 43.08 | 34.45 | 31.54 | 76.84 |
| Payable days | 218.97 | 182.04 | 217.67 | 296.18 | 324.20 |
| Valuation Parameters | |||||
| PER(x) | 30.25 | 45.04 | - | - | - |
| PCE(x) | 22.84 | 35.08 | - | - | - |
| Price/Book(x) | 3.74 | 3.35 | - | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 5.78 | 6.42 | 1.24 | 1.99 | 1.39 |
| EV/Core EBITDA(x) | 16.98 | 23.47 | 5.99 | 4.31 | 8.18 |
| EV/EBIT(x) | 19.86 | 27.75 | 7.73 | 4.84 | 11.55 |
| EV/CE(x) | 2.90 | 2.34 | 0.59 | 0.66 | 0.39 |
| M Cap / Sales | 5.52 | 6.62 | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 58.85 | 85.65 | 507.07 | 149.38 | - |
| Core EBITDA Growth(%) | 97.67 | 145.46 | 171.43 | 577.75 | - |
| EBIT Growth(%) | 99.88 | 167.87 | 135.95 | 753.34 | - |
| PAT Growth(%) | 108.31 | 78.36 | 287.88 | 750.96 | - |
| EPS Growth(%) | 97.01 | 23.33 | 20.01 | 657.93 | - |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.35 | 0.39 | 1.22 | 1.34 | 0.39 |
| Current Ratio(x) | 1.92 | 3.00 | 1.01 | 0.99 | 2.74 |
| Quick Ratio(x) | 1.71 | 2.77 | 0.86 | 0.93 | 2.44 |
| Interest Cover(x) | 7.36 | 4.27 | 3.64 | 6.82 | 3.02 |
| Total Debt/Mcap(x) | 0.09 | 0.12 | - | - | - |
Compare Financial Ratios of peers of SENORES PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SENORES PHARMACEUTICALS | ₹6,218.9 Cr | -0.5% | -7.2% | 98.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹434,280.0 Cr | -2.4% | -6.2% | 11.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹246,737.0 Cr | -3.3% | 1.4% | 57.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,129.0 Cr | -4.5% | -4% | 35.9% | Stock Analytics | |
| CIPLA | ₹108,808.0 Cr | -3.6% | -5% | -10.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,170.0 Cr | -0.2% | 2.5% | -3% | Stock Analytics | |
SENORES PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SENORES PHARMACEUTICALS | -0.5% |
-7.2% |
98.4% |
| SENSEX | -2.3% |
-6.6% |
-12% |
You may also like the below Video Courses
